Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Similar articles for PubMed (Select 21575885)

1.

Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease.

Levine A, Turner D.

J Crohns Colitis. 2011 Jun;5(3):222-6. doi: 10.1016/j.crohns.2011.01.006. Epub 2011 Mar 30.

2.

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.

Dig Liver Dis. 2004 May;36(5):342-7.

PMID:
15191204
3.

The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.

Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, Szymanska S, Woynarowski M, Ryzko J.

Eur J Gastroenterol Hepatol. 2012 May;24(5):495-500. doi: 10.1097/MEG.0b013e32835159f2.

PMID:
22387887
4.

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group.

Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. Epub 2006 Dec 3.

PMID:
17324398
5.

Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.

Prantera C, Berto E, Scribano ML, Falasco G.

Ital J Gastroenterol Hepatol. 1998 Dec;30(6):602-6.

PMID:
10076781
6.

[Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].

Gong JF, Niu LY, Wei XW, Zhu WM, Li N, Li JS.

Zhonghua Wai Ke Za Zhi. 2009 Aug 15;47(16):1213-7. Chinese.

PMID:
19781164
7.

Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity.

Shafran I, Burgunder P.

Dig Dis Sci. 2010 Apr;55(4):1079-84. doi: 10.1007/s10620-009-1111-y. Epub 2010 Jan 29.

PMID:
20112064
8.

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.

Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR.

Gastroenterology. 2002 Jul;123(1):33-40.

PMID:
12105831
9.

Pediatric Crohn's disease activity at diagnosis, its influence on pediatrician's prescribing behavior, and clinical outcome 5 years later.

Mesker T, van Rheenen PF, Norbruis OF, Uitentuis J, Waalkens HJ, Gonera G, van Overbeek LA, Butler J, Rings EH.

Inflamm Bowel Dis. 2009 Nov;15(11):1670-7. doi: 10.1002/ibd.20950.

PMID:
19418567
10.

Tolerance and efficacy of azathioprine in pediatric Crohn's disease.

Riello L, Talbotec C, Garnier-Lengliné H, Pigneur B, Svahn J, Canioni D, Goulet O, Schmitz J, Ruemmele FM.

Inflamm Bowel Dis. 2011 Oct;17(10):2138-43. doi: 10.1002/ibd.21612. Epub 2011 Jan 13.

PMID:
21910176
11.

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics.

Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J.

J Antimicrob Chemother. 1997 Mar;39(3):393-400.

12.

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P.

Am J Gastroenterol. 2011 Apr;106(4):661-73. doi: 10.1038/ajg.2011.72. Epub 2011 Mar 15. Review. Erratum in: Am J Gastroenterol. 2011 May;106(5):1014. Abadir, A [corrected to Abadir, Amir].

PMID:
21407187
13.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.

Gastroenterology. 2007 May;132(5):1672-83. Epub 2007 Mar 21.

PMID:
17484865
14.

Open label trial of oral clarithromycin in active Crohn's disease.

Leiper K, Morris AI, Rhodes JM.

Aliment Pharmacol Ther. 2000 Jun;14(6):801-6.

15.

Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children.

Mahdi G, Israel DM, Hassall E.

Am J Gastroenterol. 1996 Jul;91(7):1355-9.

PMID:
8677994
16.

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS.

Am J Gastroenterol. 2003 Apr;98(4):833-8.

PMID:
12738464
17.

Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.

Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R.

J Crohns Colitis. 2013 Dec 15;7(12):958-67. doi: 10.1016/j.crohns.2013.02.016. Epub 2013 Mar 18.

18.

Combination ciprofloxacin and metronidazole for active Crohn's disease.

Greenbloom SL, Steinhart AH, Greenberg GR.

Can J Gastroenterol. 1998 Jan-Feb;12(1):53-6.

PMID:
9544412
19.

Metronidazole plus ciprofloxacin therapy for active Crohn's disease.

Ishikawa T, Okamura S, Oshimoto H, Kobayashi R, Mori M.

Intern Med. 2003 Apr;42(4):318-21.

20.

Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.

Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E.

Dig Dis Sci. 2009 Aug;54(8):1746-52. doi: 10.1007/s10620-008-0545-y. Epub 2008 Nov 12.

PMID:
19003531
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk